Texas Oncology
Austin, Texas
In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Debra Patt, MD, PhD, MBA, highlights how value-based care models affect treatment decisions for patients with HER2-positive metastatic breast cancer.
A key opinion leader describes treatment access considerations among patient with HER2-positive metastatic breast cancer.
Debra Patt, MD, PhD, MBA, explains how clinical practice has adapted to the use of targeted therapies to treat HER2-positive metastatic breast cancer.
Debra Patt, MD, PhD, MBA, discusses the cost considerations of conventional and novel therapies for HER2-positive metastatic breast cancer.
An expert in HER2-positive metastatic breast cancer discusses the new targeted treatment regimens for patients.
Debra Patt, MD, PhD, MBA, describes the frontline standards of care and the factors involved in deciding on a treatment for human epidermal growth factor receptor 2-positive metastatic breast cancer.
